Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive Article from MarketBeat.com A Fresh IPO That Long-Term Investors Shouldn't IgnoreSubmitted by Jordan Chussler. Article Published: 1/14/2026. 
At a Glance - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week companies go public, and a handful of them can offer considerable short-term upside potential. They also carry substantial downside risk. Even so, some recent IPOs may deserve a place in buy-and-hold portfolios, including a biotechnology company in the healthcare sector that just went public. Last Year's IPO Success Stories Last year is a strong example of why IPOs shouldn't be dismissed by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators captured a nearly 359% gain before the stock had been listed for 30 days, but longer-term holders are still enjoying strong returns. Others, such as Medline (NASDAQ: MDLN), refute the idea that all IPOs are high-risk startups. The medical products and services provider, which publicly debuted in December 2025, was founded in 1966 and already has a market cap above $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—famous for its packages of bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44%, or $1 per share annually, making it an immediate consideration for income investors. After its IPO and with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for diagnostics and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals combine radioactive isotopes with a targeting module that seeks out particular cells (for example, cancer cells) to deliver localized doses of radiation, minimizing harm to healthy tissue that conventional treatments might affect. Industry consultancy Grand View Research estimates the global nuclear medicine market at nearly $18 billion in 2024 and forecasts it will reach almost $35 billion by 2030—a compound annual growth rate of 10.16%. For Boston-based Aktis Oncology, Grand View Research notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States as the predominant player. Aktis Oncology's Clinical-Stage Profile Wall Street expects biotech IPO activity to rebound in 2026 after a slowdown in 2025. Aktis Oncology, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and raised $318 million—one of the larger biotech IPO financings in recent memory—giving the firm a market cap of about $3.34 billion. According to the company's prospectus, the executive team includes drug development, approval and commercialization veterans who have participated in bringing 14 currently FDA-approved products to market. On a technical level, Aktis develops targeted alpha radiopharmaceuticals, a class of precision cancer drugs that uses proprietary technology to target solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but it attracted significant attention from Eli Lilly (NYSE: LLY), which anchored its IPO. Per Reuters, Eli Lilly purchased $100 million worth of AKTS shares. This builds on a 2024 partnership in which Lilly committed $60 million in cash and made an equity investment in Aktis, with potential milestone payments that could exceed $1 billion. The significance of Lilly's backing is notable: at about $1.01 trillion, Eli Lilly is one of the largest pharma companies by market cap after net income jumped nearly 109% year-over-year from 2023 to 2024. With both an equity stake and a $100 million share purchase, the maker of Zepbound has a sizable financial interest in Aktis's success. That said, investors should remember Aktis remains clinical-stage and pre-revenue. Its future depends on the outcomes of clinical trials, regulatory approvals and successful commercialization. Eli Lilly's support reduces some execution risk but does not eliminate the fundamental uncertainties inherent to biotech. Speculative investors may find opportunity here, but conservative investors should weigh position size and time horizon carefully.
| 
